Key result
Higher baseline plasma levels of PRO-C3 were associated with an increased risk of cardiovascular mortality over a three-year follow-up period (OR 1.56; 95% CI 1.008-2.43; p=0.046).
Why the study?
There is a clinical need for improved non-invasive, cheap, and easily accessible methods to evaluate individuals at risk of cardiovascular disease.
Do elevated baseline plasma levels of PRO-C3 predict arterial stiffness and cardiovascular death in the SUMMIT cohort?
Cohort (n=1,354)
Do elevated baseline plasma levels of PRO-C3 predict arterial stiffness and cardiovascular death in the SUMMIT cohort?
Odds Ratio: 1.56 (95% CI 1.008–2.43)
p-value: p=0.046
Elevated circulating PRO-C3 levels are significantly associated with increased arterial stiffness and a higher risk of cardiovascular mortality, suggesting its potential as a novel biomarker for declining vascular health.
PRO-C3 may mark vascular stenosis and CVD risk; leaves open its added value for risk stratification.
BACKGROUND AND AIMS: The N-terminal propeptide of type III collagen (PRO-C3) assay measures a pro-peptide released during type III collagen synthesis, an important feature of arterial stiffening and atherogenesis. There is a clinical need for improved non-invasive, cheap and easily accessible methods for evaluating individuals at risk of cardiovascular disease (CVD). In this study, we investigate the potential of using circulating levels of PRO-C3 to mark the degree of vascular stenosis and risk of cardiovascular events. METHODS: Baseline plasma levels of PRO-C3 were measured by ELISA in subjects belonging to the SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT) cohort (N = 1354). Associations between PRO-C3 levels with vascular characteristics, namely stiffness and stenosis, and risk of future cardiovascular events were explored. Subjects were followed up after a median of 35 months (interquartile range 34-36 months), with recorded outcomes cardiovascular death and all-cause mortality. RESULTS: We found a correlation between PRO-C3 levels and pulse wave velocity (rho 0.13, p = 0.000009), a measurement of arterial stiffness. Higher PRO-C3 levels were also associated with elevated blood pressure (rho 0.07, p = 0.014), as well as risk of cardiovascular mortality over a three-year follow-up period (OR 1.56, confidence interval 1.008-2.43, p = 0.046). CONCLUSIONS: Elevated circulating PRO-C3 levels are associated with arterial stiffness and future cardiovascular death, in the SUMMIT cohort, suggesting a potential value of PRO-C3 as a novel marker for declining vascular health.
No takes yet. Share an insight, caveat, or question.
Genovese et al. (2023) conducted a cohort in At risk of cardiovascular disease (n=1,354). Baseline plasma levels of PRO-C3 was evaluated on cardiovascular mortality (OR 1.56, 95% CI 1.008-2.43, p=0.046). Higher baseline plasma levels of PRO-C3 were associated with an increased risk of cardiovascular mortality over a three-year follow-up period (OR 1.56; 95% CI 1.008-2.43; p=0.046).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: